(4S)-N-[(2S)-6-[hexadecanoyl(hydroxy)amino]-1-[[(2S)-3-[[(3S)-1-hydroxy-2-oxoazepan-3-yl]amino]-3-oxo-2-[4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoylamino]propyl]amino]-1-oxohexan-2-yl]-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide | 1268337-63-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S)-N-[(2S)-6-[hexadecanoyl(hydroxy)amino]-1-[[(2S)-3-[[(3S)-1-hydroxy-2-oxoazepan-3-yl]amino]-3-oxo-2-[4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoylamino]propyl]amino]-1-oxohexan-2-yl]-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide
• CAS: 1268337-63-8
• 化学式: C₆₀H₉₅N₇O₁₅
• 分子量: 1154.45
• InChiKey: ICYNPHBZWFRQSG-UXMZBLNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  82
• 可旋转键数：
  33
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  285
• 氢给体数：
  7
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  dihydroartemisinin 在 sodium periodate 、 ruthenium(III) chloride monohydrate 、 硫酸 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 反应 73.0h， 生成 (4S)-N-[(2S)-6-[hexadecanoyl(hydroxy)amino]-1-[[(2S)-3-[[(3S)-1-hydroxy-2-oxoazepan-3-yl]amino]-3-oxo-2-[4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoylamino]propyl]amino]-1-oxohexan-2-yl]-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide
  参考文献：
  名称：

  Design, Synthesis, and Study of a Mycobactin−Artemisinin Conjugate That Has Selective and Potent Activity against Tuberculosis and Malaria

  摘要：

  Although the antimalarial agent artemisinin itself is not active against tuberculosis, conjugation to a mycobacterial-specific siderophore (microbial iron chelator) analogue induces significant and selective anti-tuberculosis activity, including activity against multi-and extensively drug-resistant strains of Mycobacterium tuberculosis. The conjugate also retains potent antimalarial activity. Physicochemical and whole-cell studies indicated that ferric-to-ferrous reduction of the iron complex of the conjugate initiates the expected bactericidal Fenton-type radical chemistry on the artemisinin component. Thus, this "Trojan horse" approach demonstrates that new pathogen-selective therapeutic agents in which the iron component of the delivery vehicle also participates in triggering the antibiotic activity can be generated. The result is that one appropriate conjugate has potent and selective activity against two of the most deadly diseases in the world.

  DOI：

  10.1021/ja109665t